Abstract
Many patients with asthma, including asthma with an allergic phenotype, also have type 2 (T2) inflammation. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/13, key and central drivers of T2 inflammation in multiple diseases. In QUEST (NCT02414854), add-on dupilumab 200 or 300mg q2w vs placebo significantly reduced severe exacerbations, improved pre-bronchodilator FEV1, and was well tolerated in patients with uncontrolled, moderate-to-severe asthma, with greater effects in patients with elevated T2 biomarkers at baseline (blood eosinophils ≥150cells/μL or FeNO ≥25ppb).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
